Page last updated: 2024-11-07

kt 6149

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KW 2149: derivative of mitomycin C; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108151
MeSH IDM0161116

Synonyms (20)

Synonym
e-90/007
kt-6149
kw-2149
kt6149
7-n-((2-((2-(r-l-glutamylamino)ethyl)dithio)ethyl))mitomycin c
7-n-(2-((2-(gamma-l-glutamylamino)ethyl)dithio)ethyl)mitomycin c
l-glutamine, n-(2-((2-(((1as,8s,8ar,8bs)-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,4,7,8,8a,8b-octahydro-8a-methoxy-5-methyl-4,7-dioxoazirino(2',3':3,4)pyrrolo(1,2-a)indol-6-yl)amino)ethyl)dithio)ethyl)-
kw 2149
l-glutamine, n-(2-((2-((8-(((aminocarbonyl)oxy)methyl)-1,1a,2,4,7,8,8a,8b-octahydro-8a-methoxy-5-methyl-4,7-dioxoazirino(2',3':3,4)pyrrolo(1,2-a)indol-6-yl)amino)ethyl)dithio)ethyl)-, (1as-(1a-alpha,8-beta,8a-alpha,8b-alpha))-
118359-59-4
ak8dki0kmn ,
kt 6149
unii-ak8dki0kmn
7-n-(2-((2-(gamma-glutamylamino)ethyl)dithio)ethyl)mitomycin c
DTXSID10922668
5-hydroxy-5-{[2-({2-[(8-{[hydroxy(imino)methoxy]methyl}-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-6-yl)amino]ethyl}disulfanyl)ethyl]imino}norvaline
(2s)-2-amino-5-[2-[2-[[(4s,6s,7r,8s)-8-(carbamoyloxymethyl)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-11-yl]amino]ethyldisulfanyl]ethylamino]-5-oxopentanoic acid
(2s)-5-amino-2-[2-[2-[[(4s,6s,7r,8s)-8-(carbamoyloxymethyl)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-11-yl]amino]ethyldisulfanyl]ethylamino]-5-oxopentanoic acid
AKOS040752288
l-glutamine, n-[2-[[2-[[(1as,8s,8ar,8bs)-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,4,7,8,8a,8b-octahydro-8a-methoxy-5-methyl-4,7-dioxoazirino[2',3':3,4]pyrrolo[1,2-a]indol-6-yl]amino]ethyl]dithio]ethyl]-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications."( In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.
Bast, A; Haenen, GR; van Acker, FA; van Acker, SA; van der Vijgh, WJ,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18."( Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" The aim of this phase I study was to determine the toxicity profile and the optimal dosage of KW-2149."( Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (16.67)18.7374
1990's27 (75.00)18.2507
2000's3 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.23 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.69%)5.53%
Reviews4 (10.26%)6.00%
Case Studies1 (2.56%)4.05%
Observational0 (0.00%)0.25%
Other31 (79.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]